Consequently, mitogen-activated protein kinase kinase (MEK) inhibitors (MEKi) and BRAF inhibitors (BRAFi) have been developed, and clinical trials have been designed to assess their efficacy based on a predefined genetic alteration detected in pediatric gliomas [56]. This evidence concerns the gene BRAF and glioma.